Matthew Cooper, Professor
Professor Matt Cooper completed his PhD in 1995 and then spent 13 years in the UK, first at the University of Cambridge, then 9 years in start-ups and biotechnology companies. He returned to Australia in 2009 as a NHMRC Australia Fellow, at the University of Queensland, where he is currently driving new antibiotic and bacterial diagnostic R&D. He was Managing Director of Cambridge Medical Innovations (part of Alere Inc.) and CSO of Akubio, and has more than 100 scientific articles, 2 books, 20 patents, and has helped launch many products on the market today.
Frank Fildes, Professor
Frank Fildes is an independent Director who has been a Board member of a number of biotechnology and pharmaceutical companies, including ProStrakan PLC, ProSkelia SA, Flamel Technologies SA, Keryx Biopharmaceuticals Inc. and Piramed Pharma Ltd. In addition, he is Principle of Fildes Partners Ltd, through which he advises health care companies and investment funds and which has included the Advisory Boards of Apax Partners Ltd, Merlin Biosciences Ltd, UCB Pharma SA and Cancer Research UK. He is currently a Board Director of Flamel Technologies SA, a member of the Project Review Board of Ferring Pharmaceuticals SA and the Business Development Board of Sunstone Capital A/S. At the end of 2002, Dr Fildes retired from AstraZeneca Pharmaceuticals where he was Senior Vice President, Head of Global Development. In this role he led the pre-clinical and clinical functions responsible for the development and technical/clinical support of AstraZeneca products around the world. During his earlier career with Zeneca and ICI Pharmaceuticals, he held a range of senior R&D Management positions, including Senior VP Pre-clinical Sciences, Director of Global Projects where he was responsible for portfolio and project management, and Head of Pharmaceutical Development. Dr Fildes is a physical chemist who trained at the University of Liverpool in the UK and Princeton University in the US. He is a Fellow of the Royal Society of Medicine and the Royal Society of Chemistry and in 2001, he was appointed an Honorary Doctor of Science by the University of Bradford.
David Livermore, Professor
Professor Livermore gained his BSc in 1978 and his PhD in 1983. He worked at the London Hospital Medical College from 1980 until 1997 when he joined the Health Protection Agency, becoming Director of its Antibiotic Resistance Monitoring and Reference Laboratory in 1998, where he remained until October 2011. In October 2011 he became Professor of Medical Microbiology at the University of East Anglia, with 30% of his time supplied back to the Health Protection Agency as its Lead on Antibiotic Resistance. He also consults widely for the pharmaceutical and diagnostics industries. Prof Livermore has broad interests on the evolution and epidemiology of antibiotic resistance. b-Lactamases are a particular interest and his work here is centred on the emergence and spread of ‘CTX-M’ extended-spectrum types, and on carbapenemases, particularly the newly-discovered NDM-1 type, which received extensive media coverage. Prof Livermore sits on several learned society committees and has edited for several journals including Journal of Antimicrobial Chemotherapy and Journal of Medical Microbiology and, currently, International Journal of Antimicrobial Agents.
Bruce Montgomery, Dr.
Dr. Montgomery is both a physician scientist and an entrepreneur that has been a leader in bringing new discoveries related to pulmonary and critical care medicine to the bedside. He has led development teams for new medical therapies for patients with cystic fibrosis, including Cayston, TOBI, and Pulmozyme, all improving respiratory symptoms in cystic fibrosis patients. In the 1980’s he co-invented aerosolized pentamidine, a prophylaxis for PCP, then the most common cause of death in patients with AIDS. He is an inventor on 18 US patents. He has been a CEO or the research head of three Seattle based biotech companies and a SVP of Gilead Sciences. Dr. Montgomery received his B.S. in Chemistry and M.D. degrees from the University of Washington and is a board-certified internist and pulmonologist.
Brad Spellberg, Professor
Professor Spellberg is Associate Professor of Medicine at the David Geffen School of Medicine at UCLA and the Harbor-UCLA Medical Center. In addition Prof Spellberg is Associate Program Director for the Internal Medicine Residency Training Program at Harbor-UCLA Medical Center. He received his BA in Molecular Cell Biology-Immunology in 1994 from UC Berkeley. He then attended medical school at the Geffen School of Medicine at UCLA, where he received numerous academic honors. Prof. Spellberg completed his Residency in Internal Medicine and subspecialty fellowship in Infectious Diseases at Harbor-UCLA Medical Center, where he received the Department of Medicine Subspecialty Fellow of the Year award. Prof. Spellberg serves as Medical Director for Clinical Research Solutions, a clinical trials unit which supports conduct of clinical research at Harbor-UCLA Medical Center. Prof. Spellberg has worked with the Infectious Diseases Society of America (IDSA) to attempt to bring attention to the problems of increasing drug resistance and decreasing new antibiotics. His research regarding new drug development has been a cornerstone of the IDSA’s white paper “Bad Bugs, No Drugs”, and has been cited extensively in medical literature and on Capitol Hill. He is a Fellow in the IDSA and joined the IDSA’s Antimicrobial Availability Task Force (AATF) to continue working on this critical issue. As a member of the AATF, he has first-authored numerous IDSA position papers and review articles relating to public policy of antibiotic resistance and antibiotic development. Finally Professor Spellberg is the author of “Rising Plague”, which he wrote to inform and educate the public about the crisis in antibiotic resistant infections and lack of antibiotic development.